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Abstract
Cancer patients are at higher risk of tuberculosis (TB) infection, especially in hospital set-
tings with high TB/HIV burden. The study was implemented among adult patients admitted
to the largest tertiary-level referral hospital in Botswana. We estimated the TB prevalence at
admission and the rate of newly diagnosed TB after hospitalization in the medical and oncol-
ogy wards, separately. Presumptive TB cases were identified at admission through symp-
tom screening and underwent the diagnostic evaluation through GeneXpert. Patients with
no evidence of TB were followed-up until TB diagnosis or the end of the study. In the medical
and oncology wards, four of 867 admitted patients and two of 240 had laboratory-confirmed
TB at admission (prevalence = 461.4 and 833.3 per 100,000, respectively.) The post-admis-
sion TB rate from the medical wards was 28.3 cases per 1,000 person-year during 424.5 fol-
low-up years (post-admission TB rate among HIV-positive versus. -negative = 54.1 and 9.8
per 1,000 person-year, respectively [Rate Ratio = 5.5]). No post-admission TB case was
detected from the oncology ward. High rates of undetected TB at admission at both medical
and oncology wards, and high rate of newly diagnosed TB after admission at medical wards
suggest that TB screening and diagnostic evaluation should target all patients admitted to a
hospital in high-burden settings.
Introduction
Nosocomial transmission of tuberculosis (TB) has remained a persistent problem in low
resource settings.[1, 2] Overcrowding and limited implementation of infection control prac-
tices make healthcare facilities highly vulnerable to TB transmission.[3] TB transmission in
healthcare facilities not only puts healthcare workers at higher risk of TB but can also lead to
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increased TB transmission in the community after infected patients are discharged from the
hospital.[2] Consequently, health facilities may serve as important drivers of the TB epidemic
in the general population.[1, 4]
Nosocomial TB transmission is a greater concern in areas where a high proportion of peo-
ple who seek care are susceptible to TB, such as HIV/AIDS patients and patients receiving can-
cer treatment.[1, 5, 6] Immunocompromised status among HIV positive patients increases the
risk of disease progression to active TB once they are infected. Patients with cancers are also
immunosuppressed as a combination of their primary diseases and cancer-related treatments.
[5, 7, 8] In addition to the possible biological relationship, shared risk factors with TB such as
smoking, alcohol consumption, and chronic obstructive pulmonary disease may increase TB
risk among cancer patients. However, there is still a dearth of information on the burden of
TB disease among cancer patients, especially in high HIV and TB burden countries.[7]
Accordingly, TB cases may have been missed in routine practice because of lower suspicion of
TB in those target populations. No other previous studies have conducted active case finding
in oncology ward, nevertheless.[5]
In this study, we explored the burden of TB disease among hospitalized patients at the larg-
est main tertiary-level referral hospital, Princess Marina Hospital, in Gaborone, Botswana. We
first aimed to compare the TB prevalence among patients admitted to the medical and oncol-
ogy wards at the day of their admission. Second, we estimated the rate of newly diagnosed TB
cases presenting after hospitalization, or post-admission TB rate, in medical and oncology
wards. In this study, we did not use the terms ‘incident’ or ‘co-prevalent’, because we could not
confirm with molecular epidemiology. We instead indicated the TB cases identified after hos-
pitalization as ‘post-admission’ or ‘newly diagnosed after admission’. We also compared the
relative risk of post-admission TB rate among HIV-positive and HIV-negative patients.
Materials and methods
Study setting
Botswana is a country of hyper-endemic for TB and HIV, with the TB incidence rate of 326
per 100,000 and about 70% of TB patients were co-infected with HIV/AIDS.(9, 10) According
to the Botswana National TB Program (BNTP) guidelines, all patients aged 15 years or older
are screened for TB symptoms at healthcare facilities on their admission. Patients reporting
cough of any duration, night sweats, chest pain, or weight loss during the prior month are con-
sidered presumptive TB cases. Presumptive TB patients provide one sputum specimen, self-
produced or induced, for TB diagnostic evaluation by GeneXpert MTB/RIF (Xpert), as recom-
mended by the World Health Organization (WHO). The Xpert has been the primary diagnosis
tool since 2016 in Botswana. Presumptive TB patients whose Xpert does not detect Mycobacte-
rium tuberculosis undergo Xpert testing a second time together with clinical assessment and
chest X-ray. All diagnosed TB patients start on TB therapy according to the BNTP guidelines.
Study population
Between August 2016 and December 2017, we recruited patients who were admitted to the
general medical and oncology wards at the Princess Marina Hospital. All patients in the oncol-
ogy ward had a biopsy-proven cancer diagnosis. All patients in the hospital aged 15 years or
older were screened for TB symptoms at admission. Patients who were non-presumptive TB
cases and who were ruled out for TB after confirmatory testing were enrolled for a follow-up
study. Enrolled patients were screened daily for TB symptoms during their stay at the hospital
and the diagnostic evaluations were performed as indicated by the attending physician. They
were technically followed up to 21 months, from their admission to April 2018, however, the
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final follow-up was 18 months, counted from August 2016 until January 2018. We assumed a
three-month of lag time between TB occurrence and the time it would be captured at the
BNTP database. We accounted the lag time for person-time calculation by subtracting three
months from the actual end period of the follow-up.
Laboratory procedures
One sputum specimen per patient was voluntarily collected from presumptive TB patients and
evaluated with Xpert or smear microscopy at the Princess Marina Hospital Clinical Labora-
tory. Only when the Xpert testing was not possible due to stock out or maintenance issues, the
smear microscopy replaced the Xpert.
Demographic and clinical measures
At baseline, patients’ characteristics were collected through face-to-face interviews and
abstraction of electronic- and paper-based medical records. Information regarding demo-
graphic characteristics, HIV status, treatment by antiretroviral therapy, malignancies,
immune-suppressive therapies, and dates of hospitalization were collected. Rapid HIV testing
was performed for all persons presenting to the hospital as a part of routine care, following the
Botswana HIV testing algorithms as recommended by the WHO. [9, 10]
Ascertainment of post-admission TB during the follow-up
The patients, who had no evidence of TB at the time of their admission, were followed until
diagnosed as TB or by the end of the study protocol (April 30th, 2018), whichever came first.
Of those patients, we excluded the patients who did not agree with participation in the study,
those whose assigned ward was missing, those whose TB diagnosis date, treatment date, or dis-
charge date was before or on the time of hospital admission, and those whose discharged data
had TB records but no diagnosis date. The patients who have developed TB during the hospi-
talization or after discharge were considered the post-admission TB cases. To identify TB cases
occurring after their discharge, we matched our database with the BNTP database by patients’
national identification number and their name at the end of the follow-up period. To capture
any missing cases and extra-pulmonary TB cases, we also reviewed the medical record when
the patients were discharged.
Statistical analyses
Patients’ characteristics were described by percentages for categorical variables and means and
standard deviations for continuous variables. The prevalence at admission was calculated by
the number of TB cases on admission through the screening process divided by the total num-
ber of admitted patients who went through the symptom-based screening during the study
period. The post-admission TB rate was calculated as the number of new TB cases identified
after admission and during the study period, divided by the sum of person-times of all patients
who were at risk. The post-admission TB rate was estimated within HIV positive and negative
populations separately, and compared by calculating the rate ratio. We calculated 95% confi-
dence intervals (CI) for TB prevalence at admission, the post-admission TB rates, and the rate
ratio. TB cases’ person-times were interval days from hospital admission to TB diagnosis.
Non-TB cases’ person-times were interval days between hospital admission and three months
(90 days) prior to the end of the study protocol, January 30th, 2018. The entire patient popula-
tion’s and the TB patients’ median hospitalization period was also estimated, when both
Tuberculosis in medical and oncology wards in Botswana
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admission and discharge dates were reported. All statistical analyses were performed using R
version 3.0.4. (The R Project for Statistical Computing; www.r-project.org)
Ethical considerations
The Botswana Ministry of Health Human Research Development Committee, the Princess
Marina Hospital Ethical Committee, the University of Pennsylvania IRB, and the University of
California Los Angeles IRB approved the study. The written informed consent was obtained
from the all participants.
Results
During the recruitment period, there were 1,400 patients admitted to the hospital; 1,155
(82.5%) to the medical wards versus 245 (17.5%) to the oncology ward. In the medical and the
oncology wards respectively, 867 (75%) and 240 (98%) of admitted patients went through the
symptom screening process. The patients screened for TB symptoms at admission were older
from the oncology ward, and a higher proportion were female and HIV infected. (Table 1)
Among the patients who were screened at the medical and oncology wards, 168 (19%) and 77
(32%) reported presumptive TB symptoms; 94 (56%) and 51 (66%) were microbiologically
tested for TB; and 4 (4%) and 2 (4%) were tested positive for TB, respectively. This corresponds
to a yield of lab-confirmed TB at admission of 0.5% (4/867) or 461.4 per 100,000 (95%
CI = 146.4–1109) and 0.8% (2/240) or 833.3 per 100,000 (95%CI = 139.6–2726) in the medical
and oncology wards, respectively. (Fig 1) Among the six prevalent TB cases, two patients from
the medical wards were HIV positive.
Overall, 406 (97%) and 178 (98%) eligible patients from the medical and the oncology
wards, respectively, were included as the final follow-up population. The total follow-up time
was 617.1 person-years, counted from August 2016 until January 2018; 424.5 and 192.6 per-
son-years in the medical and the oncology wards, respectively. The patients from the oncology
Table 1. Characteristics of study population who were screened for presumptive tuberculosis symptoms between
August 2016 and June 2017 (N = 1107).
Medical wards Oncology ward
(N = 867, 78%) (N = 240, 22%)
N (%) N (%)
Age (years) � 41.9 ± 18.5 53.5 ± 16.4
Gender
Female 495 (57%) 151 (63%)
Male 372 (43%) 89 (37%)
HIV status
Positive 327 (38%) 113 (47%)
Negative 431 (50%) 107 (45%)
Unknown 109 (13%) 20 (8%)
Presumptive TB 168 (19%) 77 (32%)
Laboratory-confirmed TB† 4 (4%) 2 (4%)
TB Prevalence (per 100,000) 461.4 833.3
� Mean ± Standard Deviation
† % was estimated out of the number of microbiologically tested presumptive cases, which was 94 and 51in the
medical and oncology wards, respectively
https://doi.org/10.1371/journal.pone.0219678.t001
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ward were more likely to be older, HIV infected, and on ART than medical wards. (Table 2)
Over 60% of the participants from both wards were female patients.
There were 12 post-admission TB cases identified from the medical wards, nine (75%) of
whom were HIV positive, whereas no post-admission TB were identified from the oncology
ward. (Table 3) All 12 TB cases were initially considered non-presumptive TB cases. Among
those, nine cases were diagnosed during hospitalization and identified by the hospital records,
eight (89%) were HIV positive. Three cases were diagnosed as TB after discharge, identified
through the BNTP database. The overall post-admission TB rate was 19.4 cases per 1,000 per-
son-year (95% CI = 10.5–33.1 cases per 1,000 person-year). The post-admission TB rate from
the medical wards was 28.3 cases per 1,000 person-year (95% CI = 15.3–48.1 cases per 1,000
Fig 1. Study flow chart. The number of not available (NA) test result = 20 in the medical and 4 in the oncology wards. TB; tuberculosis.
https://doi.org/10.1371/journal.pone.0219678.g001
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person-year). The post-admission TB rate during the hospitalization included nine TB cases
identified during 132.7 person-years of follow-up, was 67.8 cases per 1,000 person-year (95%
CI = 33.1–124.5 cases per 1,000 person-year).
The median time of hospitalization for the follow-up population was 9 days (interquartile
range [IQR] = 5–15) in the medical wards among 324 patients and 22 days (IQR = 11–32)
among 102 patients in the oncology ward. The median time between TB diagnosis and the
hospital admission was 10 days (IQR = 4–14) in the medical wards; 6 days (IQR = 4–10)
among nine HIV-positive and 35.5 days among two HIV-negative patients (35 and 36 days).
The post-admission TB rates among HIV positive and negative patients were 34.9 cases per
1,000 person-year (95% CI = 17.0–64.0) and 7.1 (95% CI = 1.2–23.6), respectively. The post-
admission TB rate ratio among HIV positive to HIV negative patients was 4.89 (95% CI = 1.2–
33.2) In the medical wards only, the post-admission TB rates among HIV positive and negative
patients were 54.1 cases per 1,000 person-year (95% CI = 26.4–99.3) and 9.8 (95% CI = 1.7–
32.5), respectively. Its rate ratio was 5.5 (95% CI = 1.3–37.4). (Fig 2)
Table 2. Characteristics of follow-up cohort who were non-presumptive tuberculosis on enrollment (N = 584).
Medical wards Oncology ward
(N = 406, 70%) (N = 178, 30%)
N (%) N (%)
Age (years)� 40.4 ±16.1 49.4 ±15.5
Gender
Male 160 (40) 67 (38)
Female 243 (60) 109 (62)
HIV
Positive 158 (39) 85 (48)
+ Antiretroviral therapy 135 (85) 80 (94)
- Antiretroviral therapy 21 (13) 4 (5)
Negative 200 (50) 70 (40)
Unknown 45 (11) 22 (12)
Chemotherapy 1 (0) 34 (19)
Radiation therapy 2 (0) 20 (11)
Newly diagnosed TB 12 (3) 0
HIV positive 9 (75) 0
Type of cancer by location
Breast - 13 (7)
Digestive/Gastrointestinal - 23 (13)
Gynecologic - 32 (18)
Head and Neck - 15 (8)
Hematologic/Blood - 8 (4)
Respiratory/Thoracic (lung) - 4 (2)
Skin - 7 (4)
Others† - 10 (13)
Unknown 66 (37)
Post-admission TB rate (cases/1,000 person-year) 28.3 0
Overall post-admission TB rate (cases/1,000 person-year) 19.4
� Mean ±Standard Deviation
† Other cancer types by location include bone (1), eye (1), germ cell (2), genitourinary (4), and musculoskeletal (2)
https://doi.org/10.1371/journal.pone.0219678.t002
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Discussion
We found the high prevalence of TB on admission among patients who were admitted to the
hospital, particularly from the oncology ward. A thorough screening and microbiologic diag-
nosis were critical for identifying TB cases that may have gone undetected if not by our screen-
ing program (no active pulmonary TB cases were identified in the oncology ward during the
year prior to the implementation of this study). Our finding of high prevalence of TB in the
oncology ward at admission aligns with previous reports of high co-existence rate of TB and
lung cancer.[8, 11] Future studies should investigate whether a causal relationship exists
between TB and cancer.[11–16]
To our knowledge, our study was the first study of active TB case finding in the oncology
ward. Currently the systematic screening for active TB is recommended among household
contacts especially young children, people living with HIV at their visit to healthcare, and
workers exposed to silica (or miners).[17] Diagnostic yields (number of TB cases diagnosed /
number screened) in these populations were estimated about 2%.[18] In contrast, the number
that needed to be screened to identify one TB case was known to be larger in hospital settings.
Though it varied across different populations, the yield was 0.7% in the previous active case
finding study in outpatient hospitals in Ghana.[18, 19] Our case finding yielded <1% in both
wards. Our yield may have been affected by low coverage of diagnostic testing as only 56% in
the medical wards and 66% in the oncology wards underwent the TB testing after showing pre-
sumptive TB symptoms. While we sought to perform microbiological testing of all patients
with TB symptoms, many patients were too ill to provide sputum samples when approached
by our research staff. This finding highlights the difficulty in achieving high rates of TB testing
in real-life inpatient settings. The lower yield may also be resulted from highly immunosup-
pressed patients who frequently experienced producing less amount of sputum or paucibacil-
lary TB.[20] The laboratory confirmation may have been challenge in these cases. Therefore,
additional research is needed to determine the most effective TB screening algorithm in this
population.[18]
We also found high post-admission TB rate after discharge from the hospital (19.4 cases per
1,000 person-year), especially from the medical wards (28.3 cases per 1,000 person-year). It
Table 3. Newly diagnosed tuberculosis patients (N = 12).
Age
(years)
Gender Previous
TB treatment
HIV status Antiretroviral therapy history Interval days�
Patient A 31 Male No Positive Yes 6
Patient B 34 Male No Positive Yes 18
Patient C 32 Male No Negative NA 36
Patient D 34 Male No Positive Yes 14
Patient E 41 Male Yes Positive Yes 1
Patient F 33 Male No Positive Yes 4
Patient G 35 Female No Positive Yes 10
Patient H 57 Male Yes Unknown NA 11
Patient I 47 Male No Positive Yes 1
Patient J 34 Male No Positive Yes 10
Patient K 40 Female No Negative NA 35
Patient L 49 Male No Positive Yes 5
� Interval days between admission date and time of diagnosis
NA; Not Applicable
https://doi.org/10.1371/journal.pone.0219678.t003
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represented a 6–9 fold higher compared to 3.26 per 1,000 persons of the annual TB incidence
in Botswana in 2016.[21] This high TB rate after hospitalization was aligned with the previous
study findings in a similar hospital setting in Botswana, which identified about 37 cases per
1,000 person-year. [2] We were not able to detect any newly diagnosed TB from the oncology
ward. The lack of detection was highly likely from patients’ high mortality during the follow-
up and high rates of existing extra-pulmonary TB. Our sample size may have been too small
and follow-up duration too short for detecting newly diagnosed TB.
Previous studies, though mostly were conducted in low TB-burden countries, presented the
increased relative risk of TB infection among cancer patients compared to the general popula-
tion. The risk varied over a wide range, depending on a type of cancer, population, and time
since diagnosis of cancer.[5, 7, 22] It was reported high at the time of diagnosis of hematologi-
cal, head and neck, or solid caners (e.g. lung cancer) in adults in Denmark, Taiwan, Korea,
and South Africa, whereas in the US-born population the risk did not increase with solid
tumors.[5, 7, 22]
Fig 2. Rate ratio of tuberculosis from HIV positive versus HIV negative. RR; Rate Ratio, TB; tuberculosis. The post-admission TB rates were estimated with 11 newly
diagnosed TB cases (9 were HIV positive and 2 were HIV negative) after excluding one case whose HIV status was unknown.
https://doi.org/10.1371/journal.pone.0219678.g002
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We performed TB screening and laboratory-based diagnostic evaluation targeting all
patients admitted to the hospital who had presumptive symptoms; however, it is possible that
patients who denied having symptoms and did not go through any diagnostic evaluations
actually had TB at baseline but were diagnosed later. Indeed, our data showed a short median
interval days from hospital admission at the medical wards to diagnosis time, 10 out of 12
cases were diagnosed as TB less than one month after hospital admission. Given that the incu-
bation period of active TB cases is believed to be around 3–9 months, [23] these post-admis-
sion TB cases may have been missed at admission. As we mentioned, without molecular
epidemiologic confirmation, we were not certain whether the 12 post-admission TB cases
were ‘incident’ after admission or ‘co-prevalent’ on admission. However, as all 12 cases were
non-presumptive during the screening on admission but presented TB shortly after admission,
the symptom-based TB screening may not have sufficient sensitivity to adequately detect TB in
health facilities. In high risk settings, universal Xpert-based TB screening for all admitted TB
patients should be warranted to diagnose unsuspected TB cases and to prevent secondary
transmission.
Our study had several limitations. First, we are likely to have missed TB cases who died
from TB-related causes. The competing risks may have led to fewer opportunities for reactiva-
tion of TB acquired in the hospital. This scenario may have been more common among cancer
patients, whose life expectancy is reduced. [5] Considering that HIV-positive patients dying
from TB would be classified as dying from HIV according to the International Classification of
Diseases (ICD),[24] both competing risks and disease misclassification may significantly affect
the finding in our study, which was conducted in the HIV-prevalent setting. In addition to the
mortality among TB/HIV co-infected patients, the morbidity may affect the finding of few
newly diagnosed TB cases. The Xpert had lower sensitivity to detect TB among HIV positive
patients than the culture diagnosis, though the Xpert is currently the primary diagnosis tool
recommended by the WHO. Regardless of repeated application of the Xpert on the second
sputum sample, together with chest X-ray and clinical diagnosis, when the first result was neg-
ative, TB infection among HIV-positive patients was likely extra-pulmonary, which were not
able to be identified based on our study procedures, unless recorded in the discharge form.
Despite extra-pulmonary TB case’s less infectiousness, it may lead to underestimation of the
burden of TB overall. Furthermore, while we collected type of cancer (63%) and its treatment
(11–19%), there were high proportions of missing and we did not collect duration of morbid-
ity. The duration of cancer morbidity is important, as the risk of active TB may be high shortly
after a cancer diagnosis and lower after time.[7] Cancer therapies may also affect the risk of
reactivation of TB differently over time and depending on the type of cancer.[6] Lastly, we
were not able to screen all eligible patients identified during the study period due to several fac-
tors such as logistical difficulties of conducting screening among severely ill patients or those
quickly discharged and/or transferred. Even the follow-up process after patients’ discharge, by
matching the discharged patient list to the BNTP database, may prevent from catching new TB
cases. We noticed a few identification information entered incorrectly through the matching
process., and, this could have underestimated newly diagnosed TB cases.
Our study findings have several implications. First, strict adherence to TB screening guide-
lines was critical for timely case detection.[5] Not only benefit to TB patients, does rapid diag-
nosis of TB also reduce the risk of hospital-associated transmission.[4, 25, 26] This is
particularly critical in settings like Botswana where populations are heavily affected by HIV
and cancer. If patients were to be detected at enrollment, it would be important to isolate
patients and follow the infection control measures to prevent hospital transmission. For
instance, in case of our study, the TB patients identified and promptly treated at admission
from the oncology ward may have prevented further TB transmission to other vulnerable
Tuberculosis in medical and oncology wards in Botswana
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cancer patients. Future studies applying molecular epidemiology are suggested to confirm
whether post-admission TB cases are truly newly diagnosed TB due to nosocomial transmis-
sion or co-prevalent TB cases that could have been undetected at admission. Furthermore, to
prevent secondary transmission after discharge, diagnostic prediction methods should be
developed to assess whether patients can be discharged safely to the community.[27]
Conclusions
We found high rates of undetected TB at admission from both the medical and oncology
wards. Post-admission TB rate after hospital admission was also high in the medical wards.
We recommend laboratory-based TB screening and diagnostic evaluation should target all
patients admitted to hospitals, and future research apply molecular epidemiology to confirm
nosocomial transmission.
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